| abstract |
A compound of formula (I):in solid form, preferably crystalline form. Preferably, the melting point of the solid MK-7 is 49-50 °C and/or it has a Karl Fischer of less than 0.3wt%, more preferably less than 0.15wt%. The compound of formula (I) finds utility as a pharmaceutical composition, nutraceutical, a food and/or in therapy, especially for the treatment of osteoporosis, cancer and/or cardiovascular disease. Alternatively, processes for the preparation of a compound of formula (I) (also known as MK-7, Vitamin MK-7, menaquinone K7) include the Kumada route involving Grignard reagents, Suzuki coupling involving boronic acids and the Biellman route involving phenylthio and/or phenylsulphonyl compounds. |